Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C

2010 ◽  
Vol 30 (10) ◽  
pp. 1454-1460 ◽  
Author(s):  
Spilios Manolakopoulos ◽  
Melanie J. Deutsch ◽  
Olga Anagnostou ◽  
Stelios Karatapanis ◽  
Elli Tiniakou ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Drug Use ◽  
Chronic Hepatitis C ◽  
Drug Users ◽  
Antiviral Treatment ◽  
Intravenous Drug ◽  
Substitution Treatment ◽  
Intravenous Drug Use

Effects of Escitalopram Prophylaxis During Antiviral Treatment for Chronic Hepatitis C in Patients With a History of Intravenous Drug Use and Depression

2014 ◽  
Vol 75 (10) ◽  
pp. 1069-1077 ◽  
Author(s):  
Daphne M. Hotho ◽  
Geert Bezemer ◽  
Bettina E. Hansen ◽  
Arthur R. Van Gool ◽  
Robert J. de Knegt ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Drug Use ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Intravenous Drug ◽  
Intravenous Drug Use ◽  
History Of

scholarly journals Characteristics of Chronic Hepatitis C Among Intravenous Drug Users: A Comparative Analysis

2010 ◽  
Vol 10 (2) ◽  
pp. 153-157 ◽  
Author(s):  
Maja Jovanović ◽  
Branislav Jovanović ◽  
Milena Potić ◽  
Ljiljana Konstantinović ◽  
Miodrag Vrbić ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Drug Use ◽  
Chronic Hepatitis C ◽  
Drug Users ◽  
Combined Treatment ◽  
Intravenous Drug ◽  
Therapy Outcome ◽  
Control Group ◽  
Intravenous Drug Users

Hepatitis C virus (HCV) usually evades the host’s immune system and persists as a chronic infection. Intravenous drug users (IVDU) represent the majority of patients infected with HCV Combined therapy of chronic hepatitis C (CHC) with peginterferon a-2a and ribavirin can be successful even when patients continue the intravenous drug use. In this study, we compared the characteristics of age, gender, genotype, and stage of fibrosis and the therapy outcome among IVDU and patients with no history of drug use. The study included 69 patients diagnosed with chronic hepatitis C, evaluated and treated at the Clinic for infectious diseases in Nis from 2005 to 2009. HCV RNA was detected by a polymerase chain reaction and the determination of genotypes was undertaken. Liver biopsies were examined histopathologicaly. Patients received a combined treatment of peginterferon alfa-2a and ribavirin. Therapy efficiency was evaluated based on the achievement of the sustained virological response (SVR). A comparison of characteristics was performed with the use of Mann-Whitney U test, chi-square (χ2) test and logistic regression. IVDU were significantly younger than patients in the control group. Prevalence of stage 1 fibrosis was significantly higher among IVDU. The therapy outcome is influenced by the patient’s age and HCV genotypes. Each year added to one patient decreased the therapy efficiency by 8.1%, while genotypes 2 and 3 experienced a therapy which was 2.08 times more efficient than in other cases. IVDU represent a specific population different from non-using patients. However, they can be treated effectively if an adequate patient-doctor relationship is established.

Lack of influence of active intravenous drug use on the management quality of patients with chronic hepatitis C

2003 ◽  
Vol 38 ◽  
pp. 134
Author(s):  
M. Cournot ◽  
F. Castel ◽  
F. Druart ◽  
T. Morin ◽  
V. Lauwers-Cances ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Drug Use ◽  
Chronic Hepatitis C ◽  
Intravenous Drug ◽  
Intravenous Drug Use ◽  
Management Quality

Compliance and effect of treatment for chronic hepatitis C (CHC) in intravenous drug users (IVDUS)

2003 ◽  
Vol 38 ◽  
pp. 165 ◽  
Author(s):  
G. Robaeys ◽  
H. Van Vlierberghe ◽  
C. Mathei ◽  
M. Van Ranst ◽  
L. Bruckers ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Drug Users ◽  
Intravenous Drug ◽  
Intravenous Drug Users ◽  
Effect Of Treatment
Sign in / Sign up

Export Citation Format

Share Document